Data monitoring committee interim reports: We must get there soon!

Currently, too many Data Monitoring Committee Reports for interim review of trial progress are quite inadequate for Data Monitoring Committees to make informed decisions about risks and benefits. Immediate serious improvement is necessary for Data Monitoring Committees to meet their ethical, clinical, and scientific responsibility to trial participants, investigators, sponsors, and participating institutions. To achieve this critical goal, all parties involved in the Data Monitoring Committee process including sponsors, investigators, Data Monitoring Committee members, and the independent statistical reporting group need to have a better understanding of the structure, function, and needs of a Data Monitoring Committee and the content of a Data Monitoring Committee Report. Training modules through the Society for Clinical Trials are now available on their website to facilitate this.

1. Friedman, L, Furberg, C, DeMets, D, et al. Fundamentals of clinical trials. 5th ed. New York: Springer, 2015.
Google Scholar | Crossref2. Ellenberg, S, Fleming, T, DeMets, D. Data monitoring committees in clinical trials: a practical perspective. 2nd ed. Chichester: John Wiley & Sons, 2019.
Google Scholar | Crossref3. DeMets, DL, Friedman, L, Furberg, CD. Data monitoring in clinical trials: a case studies approach. New York: Springer, 2005.
Google Scholar4. Herson, J. Data and safety monitoring committees in clinical trials. 2nd ed. New York: Chapman and Hall/CRC Press, 2016.
Google Scholar | Crossref5. Califf, RM, Morse, MA, Wittes, J, et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24(3): 256–271.
Google Scholar | Crossref | Medline6. Bierer, B, Li, R, Seltzer, J, et al. Responsibilities of data monitoring committees: consensus recommendations. Ther Innov Regul Sci 2016; 50(5): 648–659.
Google Scholar | SAGE Journals | ISI7. Calis, K, Archdeacon, P, Bain, R, et al. Understanding the functions and operations of data monitoring committees: survey and focus group findings. Clin Trials 2017; 14(1): 59–66.
Google Scholar | SAGE Journals | ISI8. Fleming, T, DeMets, D, Roe, MT, et al. Data monitoring committees: promoting best practices to address emerging challenges. Clin Trials 2017; 14(2): 115–123.
Google Scholar | SAGE Journals | ISI9. Lewis, R, Calis, K, DeMets, DL. Enhancing the scientific integrity and safety of clinical trials: recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. JAMA 2016; 316: 2359–2360.
Google Scholar | Crossref | Medline10. Fisher, M, Roecker, EB, DeMets, D. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Inf J 2001; 35: 115–129.
Google Scholar | SAGE Journals11. Wittes, J, Schactman, M. On independent data monitoring committees in oncology clinical trials. Chin Clin Oncol 2014; 3(3): 40.
Google Scholar | Medline12. Buhr, KA, Downs, M, Rhorer, J, et al. Reports to independent data monitoring committees: an appeal for clarity, completeness, and comprehensibility. Ther Innov Regul Sci 2018; 52(4): 459–468.
Google Scholar | SAGE Journals | ISI13. Neaton, JD, Grund, B, Wentworth, D. How to construct an optimal interim report: what the data monitoring committee does and doesn’t need to know. Clin Trials 2018; 15(4): 359–365.
Google Scholar | SAGE Journals | ISI14. DeMets, DL. The independent statistician model: how well is it working? Clin Trials 2018; 15(4): 329–334.
Google Scholar | SAGE Journals | ISI15. DeMets, DL, Califf, RM. A historical perspective on clinical trials innovation and leadership: where have the academics gone? JAMA 2011; 305: 713–714.
Google Scholar | Crossref | Medline | ISI16. DeMets, DL, Ellenberg, S. Data monitoring committees: expect the unexpected. N Engl J Med 2016; 375: 1365–1371.
Google Scholar | Crossref | Medline | ISI17. DeMets, DL, Fleming, TR, Rockhold, F, et al. Liability issues for data monitoring committee members. Clin Trials 2004; 1(6): 525–531.
Google Scholar | SAGE Journals18. Beta Blocker Heart Attack Trial (BHAT) Research Group . A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982; 247: 1707–1714.
Google Scholar19. Clinical Trials Program, Department of Biostatistics and Medical Informatics, University of Wisconsin–Madison . Sample DMC reports, 2016, https://biostat.wiscweb.wisc.edu/research/clinical-trials/statistical-data-analysis-center/DMC-reports/ (accessed 20 August 2021).
Google Scholar20. SCT DMC Training . Society for clinical trials, http://www.sctweb.org/dmctraining/
Google Scholar21. TransCelerate Biopharma Inc ., https://www.transceleratebiopharmainc.com/contact/ (accessed 20 August 2021).
Google Scholar

留言 (0)

沒有登入
gif